Dialysis symptom index burden and symptom clusters in a prospective cohort of dialysis patients

Amy S. You1 · Sara S. Kalantar1,2 · Keith C. Norris3 · Rene Amel Peralta1 · Yoko Narasaki1 · Ronald Fischman4 · Michael Fischman4 · Avedik Semerjian4 · Tracy Nakata1 · Zahra Azadbadi5 · Danh V. Nguyen6 · Kamyar Kalantar-Zadeh1 · Connie M. Rhee1

Received: 11 December 2021 / Accepted: 19 March 2022 / Published online: 16 April 2022 © The Author(s) 2022

Abstract

Background Dialysis patients experience a high symptom burden, which may adversely impact their quality of life. Whereas other specialties emphasize routine symptom assessment, symptom burden is not well-characterized in dialysis patients. We sought to examine the prevalence and severity of unpleasant symptoms in a prospective hemodialysis cohort.

Methods Among 122 hemodialysis patients from the prospective Malnutrition, Diet, and Racial Disparities in Chronic Kidney Disease (CKD) study, CKD-associated symptoms were ascertained by the Dialysis Symptom Index, a validated survey assessing symptom burden/severity (with higher scores indicating greater symptom severity), over 6/2020–10/2020. We examined the presence of (1) individual symptoms and symptom severity scores, and (2) symptom clusters (defined as ≥ 2 related concurrent symptoms), as well as correlations with clinical characteristics.

Results Symptom severity scores were higher among non-Hispanic White and Hispanic patients, whereas scores were lower in Black and Asian/Pacific Islander patients. In the overall cohort, the most common individual symptoms included feeling tired/lack of energy (71.3%), dry skin (61.5%), trouble falling asleep (44.3%), muscle cramps (42.6%), and itching (42.6%), with similar patterns observed across racial/ethnic groups. The most prevalent symptom clusters included feeling tired/lack of energy + trouble falling asleep (37.7%); trouble falling asleep + trouble staying asleep (34.4%); and feeling tired/lack of energy + trouble staying asleep (32.0%). Lower hemoglobin, iron stores, and dialysis adequacy correlated with higher individual and overall symptom severity scores.

Conclusion We observed a high prevalence of unpleasant symptoms and symptom clusters in a diverse hemodialysis cohort. Further studies are needed to identify targeted therapies that ameliorate symptom burden in CKD.
Study Design

Study Population: 122 hemodialysis patients from a prospective cohort recruited across 16 dialysis centers.

Exposure: CKD-associated symptoms assessed by the Dialysis Symptom Index (DSI) survey.

Methods: Using the DSI survey, examined:
- Individual symptoms & severity scores
- Symptom clusters (≥2 concurrent symptoms)
- Correlation of symptoms with clinical characteristics

Results

- Higher symptom severity scores in Non-Hispanic White & Hispanic patients; lower severity scores in African-American and Asian/Pacific Islander patients.
- Most prevalent symptoms: Feeling tired/lack of energy (71.3%), dry skin (61.5%), trouble falling asleep (44.3%), muscle cramps (42.6%), itching (42.6%).
- Most prevalent cluster: Feeling tired/lack of energy + trouble falling asleep (37.7%).
- Higher (worse) individual & overall symptom severity scores correlated with:
  - Lower hemoglobin
  - Lower iron indices
  - Lower dialysis adequacy

Conclusion: A high prevalence of unpleasant symptoms & symptom clusters were observed in a diverse prospective dialysis cohort. Further studies are needed to identify targeted therapies that ameliorate symptom burden in CKD.

Keywords Unpleasant symptoms · Symptom clusters · Uremia · Dialysis

Introduction

Patients with kidney failure, including those who receive maintenance dialysis therapy, experience a high prevalence of physical and emotional disease-related symptoms [1–5]. A high symptom burden has been associated with higher death risk in dialysis patients [6], as well as lower health-related quality of life (HRQOL) vis-à-vis interference with their activities of daily living and physical function, independence, social relationships and activities, and overall well-being [7, 8]. Moreover, dialysis patients oftentimes prioritize alleviation of symptoms over other health outcomes such as survival and biochemical indices [8].

Despite the high burden of unpleasant symptoms in end-stage renal disease (ESRD), they are frequently under-recognized, under-estimated, and consequently under-treated [2, 9]. Ascertainment of chronic kidney disease (CKD)-associated symptoms in dialysis patients may be challenging due to their vague nature, difficulty in objective quantification, and conflation with other co-existing comorbidities [2]. Additionally, limited patient—provider interaction time and reporting biases influenced by social/cultural factors may prelude adequate symptom assessment, leading to some patients potentially adapting to and/or minimizing their symptoms over time [10].

The use of validated assessment tools may facilitate communication between patients and their providers about the presence and/or severity of their symptoms [5]. There are multiple generic and disease-specific instruments for symptom evaluation, among which the Dialysis Symptom Index, a comprehensive 30-item survey assessing the presence and severity of unpleasant symptoms [11, 12], is the most frequently used instrument utilized in CKD and ESRD patients. While an increasing number of epidemiologic studies have sought to use the Dialysis Symptom Index to uncover the prevalence of physical and emotional symptoms in US dialysis patients [6, 11–19], comparisons of symptom burden across diverse racial/ethnic groups remain incompletely characterized.

Furthermore, whereas emerging data in other fields (i.e., oncology) show that unpleasant symptoms often occur in clusters (i.e., defined as two or more concurrent symptoms that are related to one another, which may have a more significant effect than isolated symptoms) [1, 20], there has been limited study of symptom clusters in ESRD patients receiving dialysis. To address this knowledge gap, we sought to examine the prevalence of individual symptoms, as well as pairings of symptoms within specific symptom clusters in a racially/ethnically diverse, multi-center prospective cohort from the NIH Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (MADRAD) study [21–24] who
underwent protocolized Dialysis Symptom Index survey assessments.

Methods and materials

Study population

The study population was a cohort of adult hemodialysis patients from the MADRAD study [21–24] (ClinicalTrials.gov NCT01415570), an ongoing prospective cohort study in which the impact of dietary and nutritional intake patterns upon outcomes across different racial/ethnic groups is being examined. In the MADRAD study, participants undergo protocolized collection of information on socio-demographic backgrounds, comorbidities, dialysis treatment characteristics, and validated surveys of patient-centered outcomes (e.g., Dialysis Symptom Index) every six months (i.e., every semester).

In this cross-sectional substudy, we assessed dialysis patients’ (1) individual symptom burden, ascertained by Dialysis Symptom Index surveys, as well as (2) symptom clusters among hemodialysis patients recruited across 16 outpatient dialysis facilities in Southern California over the period of June to October 2020. Patients were included provided that they completed at least one or more Dialysis Symptom Index surveys, were at least 18 years of age at the time of study entry (i.e., time of baseline Dialysis Symptom Index assessment), and had been receiving in-center hemodialysis for at least four consecutive weeks. Patients were excluded if they were actively receiving peritoneal dialysis, had a life expectancy of less than six months (i.e., defined as having a terminal disease such as metastatic cancer, or enrollment in hospice while concurrently receiving dialysis), or were unable to provide consent without a proxy. The study was approved by the Institutional Review Board committee at the University of California Irvine.

Dialysis symptom index assessment

In this study, we examined baseline Dialysis Symptom Index surveys, which were collected from in-center hemodialysis patients during their routine hemodialysis treatments. The Dialysis Symptom Index is a validated instrument to assess CKD-related unpleasant symptoms, and it is comprised of 30 questions about the presence of specific symptoms [11, 12]. For each question querying presence vs. absence of a specific symptom, symptom severity is assessed using a five-point Likert scale, with each response ranging from 0 to 4 (i.e., a response of “0” indicates “no,” whereas a response of “4” indicates “yes: very much”). The minimum–maximum Dialysis Symptom Index score ranges from 0 to 120, with higher scores indicating greater overall severity of symptoms.

In primary analyses, we examined (1) the clinical characteristics of patients reporting higher vs. lower symptom burden defined by overall symptom severity scores, as well as (2) the prevalence of individual symptoms from the Dialysis Symptom Index surveys. In secondary analyses examining groupings of symptoms, we also assessed (3) the prevalence of pairings of symptoms within specific symptom clusters categorized according to end-organ domains, namely the gastrointestinal, dermatologic, psychiatric, sleep, pain, neurologic, and endocrine systems, as well as (4) correlations of individual symptoms from the Dialysis Symptom Index surveys.

Socio-demographics, comorbidities, and dialysis treatment characteristics

At study entry, baseline information on socio-demographics, comorbid conditions, and dialysis treatment characteristics (e.g., vascular access type) were collected. Dialysis vintage was defined as the time period between the date of study entry (i.e., date of baseline Dialysis Symptom Index assessment) and the date of hemodialysis initiation. Routine dialysis laboratory measurements were performed by the outpatient dialysis laboratories on a monthly or quarterly basis using automated methods. Information on race/ethnicity was self-reported by participants.

Statistical analyses

Baseline characteristics between exposure groups (e.g., higher/lower symptom burden) were compared using chi-square, analysis of variance, and Kruskal–Wallis tests according to variable type. We first examined the distribution of the Dialysis Symptom Index severity scores and prevalence of individual symptoms in the overall cohort. In order to determine if symptoms differed across race/ethnicity, we also separately examined score distributions and prevalence of individual symptoms across racial/ethnic groups. We then assessed the prevalence of pairings of symptoms within specific symptom clusters categorized according to groupings by end-organ system. We additionally examined correlations of individual symptoms from the Dialysis Symptom Index surveys using Pearson and Spearman correlations adjusted for age, sex, and race/ethnicity. In sensitivity analyses of a subcohort of patients who had measurement of key laboratory parameters (i.e., hemoglobin, iron, dialysis adequacy, nutritional, mineral bone disease, and electrolyte values) within six months prior to or within one month after the Dialysis Symptom Index survey assessment, we examined correlations between the most proximate clinical laboratory value with overall symptom severity and individual
symptom severity scores. The analyses and figures were generated using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA), Stata version 13.1 (Stata Corporation, College Station, TX, USA), and SigmaPlot version 12.5 (Systat Software, San Jose, CA, USA).

Results

Baseline characteristics

After applying the eligibility criteria, the final study cohort was comprised of 122 hemodialysis patients, with a mean ± SD age of 60 ± 13 years, among whom 8% were non-Hispanic White, 62% were Hispanic White, 22% were Black, 6% were Asian/Pacific Islander, and 2% were of Other race/ethnicity (Table 1). In the overall cohort, the median (IQR) and minimum–maximum number of individual symptoms reported by patients was 9 (5, 13) and 0–30, respectively.

Baseline characteristics of the cohort stratified by baseline Dialysis Symptom Index overall symptom severity scores are shown in Table 1. Compared to patients in the lowest (first) Dialysis Symptom Index severity score tertile, those in the highest (third) tertile were more likely to be female, non-Hispanic White, and Hispanic White; were less likely to be Black; had longer dialysis vintages; were less likely to be married or single; and were more likely to have Medicare/Medicaid as their primary insurance.

Upon comparing the distribution of Dialysis Symptom Index symptom severity scores across racial/ethnic groups, median (IQR) values were higher in non-Hispanic White and Hispanic White patients (26 [16, 54] and 25 [12, 37], respectively), yet tended to be lower in Black and Asian/Pacific Islander patients (22 [9, 30]) and 19 [14, 46], respectively) as shown in Supplementary Table 1. Additionally, the median (IQR) number of individual symptoms reported by patients tended to be higher in non-Hispanic White and Hispanic White patients (11 [5, 19] and 10 [6, 14], respectively), yet

Table 1  Baseline characteristics according to tertiles of baseline Dialysis Symptom Index (DSI) scores

| Overall | Tertile 1 | Tertile 2 | Tertile 3 | P-value |
|---------|----------|----------|----------|---------|
| N (%)   | 122      | 40 (33)  | 39 (32)  | 43 (35) | N/A     |
| DSI score (min–max) | 0–100   | < 15     | 15– < 32 | ≥ 32    | N/A     |
| Age (mean ± SD), years | 60 ± 13 | 61 ± 12  | 58 ± 16  | 60 ± 12 | 0.50    |
| Female (%) | 51      | 43       | 54       | 56      | 0.43    |
| Race/ethnicity (%) |         |          |          |         |         |
| Non-Hispanic White | 8       | 5        | 8        | 12      | 0.72    |
| Hispanic White     | 62      | 58       | 62       | 67      |         |
| Black               | 22      | 30       | 23       | 14      |         |
| Asian/Pacific Islander | 6    | 5        | 8        | 5       |         |
| Other               | 2       | 3        | 0        | 2       |         |
| Diabetes (%)        | 67      | 70       | 59       | 72      | 0.41    |
| Vintage (mean ± SD), months | 81 ±80 | 81 ± 50  | 69 ±48   | 90 ±117 | 0.50    |
| Access (%)          |         |          |          |         |         |
| AVG/AVF             | 93      | 95       | 90       | 95      | 0.59    |
| Catheter            | 7       | 5        | 10       | 5       |         |
| Marital status (%)  |         |          |          |         |         |
| Married             | 37      | 45       | 31       | 35      | 0.20    |
| Single              | 37      | 43       | 36       | 33      |         |
| Other               | 26      | 13       | 33       | 33      |         |
| Insurance (%)       |         |          |          |         |         |
| Medicare/Medicaid   | 84      | 83       | 82       | 86      | 0.48    |
| Kaiser, Private     | 11      | 8        | 15       | 12      |         |
| Other               | 5       | 10       | 3        | 2       |         |
| BMI (mean ± SD), kg/m² | 30.1 ±7.1 | 31.4 ±7.3 | 28.7 ±7.8 | 30.2 ±5.9 | 0.37    |
| Post weight (mean ± SD), lbs | 181 ±49 | 191 ±44  | 171 ±57  | 182 ±44 | 0.34    |

SD, standard deviation; AVG/AVF, arteriovenous graft/arteriovenous fistula; BMI, body mass index; kg/m², kilogram/meter squared; lbs, pounds
were lower in Black and Asian/Pacific Islander patients (7 [4, 10] and 9 [6, 13], respectively). Supplementary Table 2 shows the baseline characteristics of the cohort stratified by racial/ethnic group.

**Individual symptoms in the overall cohort and across race/ethnicity**

The prevalence of individual symptoms from the Dialysis Symptom Index were examined in the overall cohort, among whom the most common symptoms reported included feeling tired or lack of energy (71.3%), dry skin (61.5%), trouble falling asleep (44.3%), muscle cramps (42.6%), and itching (42.6%) (Fig. 1). Given the abovementioned differences in the distribution of Dialysis Symptom Index scores across racial/ethnic groups, we also compared the burden of individual symptoms among patients of non-Hispanic White, Hispanic White, Black, and Asian/Pacific Islander background (Fig. 2A–D). Among non-Hispanic White hemodialysis patients, the most prevalent symptoms included muscle cramps (80.0%), muscle soreness (80.0%), feeling tired or lack of energy (80.0%), trouble falling asleep (60.0%), and difficulty concentrating (60.0%). However, among Black hemodialysis patients, the most common symptoms included feeling tired or lack of energy (63.0%), dry mouth (40.7%), itching (40.7%), decreased interest in sex (40.7%), and trouble falling asleep (37.0%). Yet in Hispanic hemodialysis patients, the most frequent symptoms were feeling tired or lack of energy (73.7%), dry skin (68.4%), trouble falling asleep (43.4%), numbness or tingling in feet (44.7%), muscle cramps (43.4%), or worrying (43.4%). Among Asian/Pacific Islander hemodialysis patients, prevalent symptoms included dry skin (100%), feeling tired or lack of energy (57.1%), dry mouth (57.1%), itching (57.1%), and decreased interest in sex (57.1%).

**Symptom clusters and correlations**

We examined clusters of symptoms across seven categories, including the gastrointestinal, dermatologic, psychiatric, sleep, pain, neurologic, and endocrine systems (Fig. 3). The
most prevalent pairings of symptoms within these clusters included (1) feeling tired and lack of energy + trouble falling asleep (37.7%), (2) trouble falling asleep + trouble staying asleep (34.4%), (3) feeling tired and lack of energy + trouble staying asleep (32.0%), (4) dry skin + itching (30.3%), and (5) dry skin + dry mouth (28.7%).

We also examined correlations of individual symptoms from the Dialysis Symptom Index. Using adjusted Pearson correlation, symptoms with the strongest correlations were (1) trouble falling asleep + trouble staying asleep ($r = 0.86$), (2) decreased interest in sex + difficulty become sexually aroused ($r = 0.74$), (3) nausea + vomiting ($r = 0.69$), (4) feeling nervous + feeling sad ($r = 0.63$), and (5) feeling sad + feeling anxious ($r = 0.61$) (Supplementary Table 3). Similarly, using adjusted Spearman correlations, symptom pairings with the strongest correlations were (1)
trouble falling asleep + trouble staying asleep \((r = 0.81)\),
(2) decreased interest in sex + difficulty become sexually
aroused \((r = 0.79)\), (3) nausea + vomiting \((r = 0.59)\), (4) feeling
sad + feeling anxious \((r = 0.58)\), and (5) feeling nervous + feeling sad \((r = 0.55)\) (Supplementary Table 4).

Correlations between symptoms and key clinical
c characteristics

In a subcohort of 53 patients who had measurement of
key laboratory parameters within six months prior to or
within one month after their Dialysis Symptom Index sur-
vey assessment, we examined correlations between labora-
tory values with overall symptom severity and individual
symptom severity scores with key laboratory parameters
(Supplementary Table 5). We found that there were sig-
nificant inverse correlations between lower hemoglobin
levels with higher (worse) individual symptom scores
for (1) feeling tired and lack of energy, (2) difficulty con-
centrating, and (3) dry skin. We also observed that lower
transferrin saturation levels had significant inverse cor-
rrelations with higher individual symptom scores for
(1) muscle cramps, (2) restless legs or difficulty keeping legs
still, and (3) muscle soreness, as well as higher overall
symptom severity scores. We found that lower levels of
dialysis adequacy ascertained by single-pool \(Kt/V\) and
urea reduction ratio \(\text{URR}\) had significant inverse cor-
rrelations with higher scores for (1) shortness of breath;
we additionally found that lower \(\text{URR}\) levels were signifi-
cantly correlated with higher scores for (2) vomiting, and
(3) diarrhea, and (4) cough. Both lower serum albumin
and higher phosphorus levels were significantly correlated
with higher scores for diarrhea.

Discussion/conclusion

In a well-characterized, multi-center prospective cohort of
hemodialysis patients of diverse racial/ethnic background
who underwent protocolized Dialysis Symptom Index sur-
veys, we found that the overall symptom severity scores
and prevalence of individual symptoms differed across
race/ethnicity. Upon examining the most common unpleas-
ant symptoms in the overall cohort and across racial/ethnic
groups, the most frequently reported symptoms were those
related to fatigue/energy, dermatologic conditions (i.e., dry
skin, itching), and impaired sleep. Similarly, we found that
the most prevalent clusters of symptoms occurred within
these domains.

To date, a growing number of studies have utilized
the Dialysis Symptom Index to quantify and characterize
symptom burden in ESRD patients \([6, 11–19]\). In a semi-
nal study that described the initial application of the Dialy-
sis Symptom Index in US hemodialysis patients across
three dialysis clinics, participants reported a median (IQR)
number of symptoms of 9 (6, 13) and a median (IQR) over-
all symptom severity score of 25 (14, 42) \([12]\). Among the
queried symptoms, over 50% of patients had dry skin, feel-
ings of being tired or having lack of energy, itching, and/
or bone/joint pain, with the highest mean severity scores
for individual symptoms reported for bone/joint pain, chest
pain, vomiting, difficulty becoming sexually aroused, and muscle cramps.

Subsequently, multiple international groups have sought to translate and/or cross-culturally adapt the Dialysis Symptom Index to their specific countries [6, 13, 15–17]. For example, in a study of 512 dialysis patients across 16 centers in the Netherlands, on average patients reported experiencing a mean ± SD of 11 ± 6 symptoms with an overall symptom severity score of 31 ± 22 based on a Dutch-version of the Dialysis Symptom Index [17]. In another study of 230 hemodialysis patients who underwent a Korean-version of the Dialysis Symptom Index across three hospitals in Seoul, nearly all participants (97.4%) reported having one or more symptoms, with the most prevalent physical symptoms including fatigue or weakness, dry skin, or weakness, and the most prevalent emotional symptoms including worrying, nervousness, and anxiety [16].

Despite these global efforts to advance our understanding of the scope of symptom burden in dialysis patients, there has been limited examination of how the prevalence, severity, and types of symptoms may vary among dialysis patients across diverse racial and ethnic backgrounds in the US. In a study of 78 Black and 82 White dialysis patients who underwent assessments of the Dialysis Symptom Index, Beck Depression Inventory, and Cognitive Depression Index, symptom burden was both considerable and comparable in both groups (median number of symptoms ~ 9 among both Black and White dialysis patients), and there were no observed racial differences in the overall severity of symptoms (median overall symptom severity score 25 and 24 in Black and White dialysis patients, respectively) [19]. However, in an exploratory analysis examining the importance attached to patients’ spiritual/religious beliefs, Black patients were more likely to report religious/spiritual beliefs as very important as compared with White patients (74% vs. 52%, respectively). Although importance of attachment to spiritual/religious beliefs was not correlated with symptom burden nor severity, in analyses stratified by race, correlations of the importance of spiritual/religious beliefs with Beck Depression Index and Cognitive Depression Index scores were significantly stronger among Black vs. White patients. In another study examining the interplay between cultural background and symptom burden among 75 dialysis patients across diverse racial and ethnic backgrounds in the US, on average patients reported experiencing a mean ± SD of 11 ± 6 symptoms with an overall symptom severity score of 31 ± 22 based on a Dutch-version of the Dialysis Symptom Index [17]. In another study of 230 hemodialysis patients who underwent a Korean-version of the Dialysis Symptom Index across three hospitals in Seoul, nearly all participants (97.4%) reported having one or more symptoms, with the most prevalent physical symptoms including fatigue or weakness, dry skin, or weakness, and the most prevalent emotional symptoms including worrying, nervousness, and anxiety [16].

Despite these global efforts to advance our understanding of the scope of symptom burden in dialysis patients, there has been limited examination of how the prevalence, severity, and types of symptoms may vary among dialysis patients across diverse racial and ethnic backgrounds in the US. In a study of 78 Black and 82 White dialysis patients who underwent assessments of the Dialysis Symptom Index, Beck Depression Inventory, and Cognitive Depression Index, symptom burden was both considerable and comparable in both groups (median number of symptoms ~ 9 among both Black and White dialysis patients), and there were no observed racial differences in the overall severity of symptoms (median overall symptom severity score 25 and 24 in Black and White dialysis patients, respectively) [19]. However, in an exploratory analysis examining the importance attached to patients’ spiritual/religious beliefs, Black patients were more likely to report religious/spiritual beliefs as very important as compared with White patients (74% vs. 52%, respectively). Although importance of attachment to spiritual/religious beliefs was not correlated with symptom burden nor severity, in analyses stratified by race, correlations of the importance of spiritual/religious beliefs with Beck Depression Index and Cognitive Depression Index scores were significantly stronger among Black vs. White patients. In another study examining the interplay between cultural background and symptom burden among 75 dialysis patients across diverse racial and ethnic backgrounds in the US, on average patients reported experiencing a mean ± SD of 11 ± 6 symptoms with an overall symptom severity score of 31 ± 22 based on a Dutch-version of the Dialysis Symptom Index [17]. In another study of 230 hemodialysis patients who underwent a Korean-version of the Dialysis Symptom Index across three hospitals in Seoul, nearly all participants (97.4%) reported having one or more symptoms, with the most prevalent physical symptoms including fatigue or weakness, dry skin, or weakness, and the most prevalent emotional symptoms including worrying, nervousness, and anxiety [16].

To address this knowledge gap, we sought to characterize burden of unpleasant symptoms using the Dialysis Symptom Index in a diverse, multi-center US prospective hemodialysis cohort with representation of non-Hispanic White, White, Black, and Asian/Pacific Islander patients. We found that overall symptom severity scores and total number of reported symptoms tended to be higher among patients of non-Hispanic White and Hispanic race/ethnicity (i.e., suggesting higher self-reported symptom burden), whereas scores and symptom number tended to be lower in patients of Black and Asian/Pacific Islander race/ethnicity (i.e., suggesting lower self-reported symptom burden). With respect to types of symptoms, there were commonalities across racial/ethnic groups, with non-Hispanic White, Black, Hispanic White, Asian/Pacific Islander patients indicating that feeling tired or lack of energy was one of the most prevalent symptoms (i.e., 57–80% of patients in each racial/ethnic group). Additionally, Black, Hispanic, and Asian/Pacific Islander patients reported trouble falling asleep (i.e., 37.0–60.0% of patients in each racial/ethnic group) and dry mouth/dry skin (i.e., 40.7–100.0% of patients in each racial/ethnic group) among the most common symptoms. There were also some notable differences in the most prevalent symptoms reported across race/ethnicity. Whereas symptoms related to muscle pain (i.e., cramps, soreness) were more dominant in non-Hispanic White and Hispanic White patients (i.e., 43.4–80.0% of patients), symptoms related to sexual dysfunction (i.e., decreased interest in sex) were more frequently reported in Black and Asian/Pacific Islander patients (i.e., 40.7–57.1% of patients). Additionally, whereas symptoms related to cognition (i.e., difficulty concentrating) and psychologic status (i.e., worrying) were among the most common in non-Hispanic White and Hispanic White patients, respectively), these symptoms were less frequently reported in those of Black and Asian/Pacific Islander background. These distinctions highlight the need for further research exploring how underlying biologic, genetic, socioeconomic, psychologic, cultural, and spiritual/religious factors influence symptom burden across racial/ethnic groups [25–27], while also underscoring the importance of using a personalized approach in the symptom management of dialysis patients [28].

Another noteworthy finding of our study was the pervasiveness of certain symptoms across clusters. In studies of non-CKD patients (i.e., oncology), there has been growing recognition that symptom clusters, in which two or more concurrent symptoms may be inter-related with respect to their underlying etiology and/or potential to alter other symptoms, may have a more significant effect than isolated symptoms [1, 20]. While many dialysis patients experience multiple concurrent symptoms, there has been limited study of symptom clusters using comprehensive, validated symptom assessment surveys such as the Dialysis Symptom Index
in this population. In this study, we found that the most prevalent pairings of symptoms within end-organ clusters tended to be those related to fatigue/energy, dermatologic conditions, and impaired sleep. Given the high prevalence of these unpleasant symptoms and their dominance within clusters, future research identifying therapies that can effectively target these symptoms may have a substantial effect on improving the health and well-being of a large proportion of dialysis patients.

While uremic toxins have traditionally been considered the main cause of CKD-associated symptoms, emerging data has shown that treatment of uremia by dialysis often fails to resolve them and can engender additional symptoms [5]. Notably, in sensitivity analyses examining the relationship between key laboratory parameters and symptoms, we found that lower levels of dialysis adequacy defined by spKt/V and URR correlated with greater severity of uremic (e.g., nausea) and volume overload (e.g., shortness of breath, cough) symptoms. Yet we also observed that worse anemia parameters defined by hemoglobin level and iron stores correlated with a broader range of symptoms, including those related to decreased energy (e.g., feeling tired or lack of energy), restless legs and muscle discomfort (e.g., restless legs or difficulty keeping legs still, muscle cramps, muscle soreness), impaired cognition (e.g., difficulty concentrating), and overall symptom burden (e.g., overall symptom severity score). As unpleasant symptoms and symptom clusters may ensue from a multitude of CKD-related complications, further studies are needed to precisely define their mechanistic underpinnings in the dialysis population.

The strengths of our study include its diverse cohort of hemodialysis patients who underwent protocolized Dialysis Symptom Index assessments; rigorous use of a symptom assessment tool that has been validated in the dialysis population; and comprehensive availability of detailed patient-level data collected in the outpatient setting. However, several limitations of our study bear mention. First, it is possible that patients who agreed to participate in the MADRAD study may be healthier than those who were not recruited, and may have thus had lower (better) symptom scores compared to the broader hemodialysis population. Second, while we had the opportunity to examine a well-characterized prospective cohort, the limited sample size of our study population likely precluded the ability to detect significant interactions on the basis of race/ethnicity (i.e., much larger sample size needed to estimate an interaction than to estimate a main effect). Third, given that our study examined Dialysis Symptom Index surveys at a single-point-in-time (i.e., baseline surveys collected at study entry), further longitudinal studies are needed to determine whether individual symptoms and symptom clusters change over time. Fourth, given that our recruitment was restricted to 16 outpatient dialysis units in Southern California, our findings may not be generalizable to other geographic regions where patients’ case-mix characteristics and dialysis practice patterns may differ. Finally, due to data limitations we were not able to examine the relationship between certain dialysis treatment characteristics (i.e., hemodialysis membrane, intra-dialytic medications) and symptom burden.

In conclusion, we observed a substantial burden of unpleasant symptoms in a diverse, prospective hemodialysis cohort, although there were notable differences in the prevalence of symptoms, overall symptom severity, and symptom types across racial/ethnic groups. We also found that symptoms related to fatigue/energy, dermatologic conditions, and impaired sleep were pervasive across racial/ethnic groups and symptom clusters. These findings underscore the critical need to incorporate standardized symptom assessments in the routine care of patients with CKD. Furthermore, future studies are needed to determine how patients’ underlying biologic, genetic, socioeconomic, psychologic, cultural, and spiritual/religious factors impact individual symptoms and symptom clusters, in order to identify targeted approaches that can ameliorate the high symptom burden of ESRD patients.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40620-022-01313-0.

Acknowledgements Portions of these data have been presented as an abstract at the 2021 National Kidney Foundation Spring Clinical Meeting, and have been presented as an abstract at the 2021 American Society of Nephrology Kidney Week Meeting.

Authors contributions The authors confirm contribution to the paper as follows: Study conception and design: ASY, KKZ, CMR; Analysis of data: ASY; Interpretation of results: ASY, SSK, KCN, RAP, YN, RF, MF, AS, TN, ZA, DVN, KKZ, CMR; Draft manuscript preparation: ASY, CMR. All authors reviewed the results and approved the final version of the manuscript.

Funding The authors are supported by the research grants from the NIH/NIDDK including R01-DK122767 (CMR), R01-DK124138 (CMR, KKZ), R01-DK092232 (DVN), and K24-DK091419 (KKZ). Funders of this study did not have any role in the study design; collection, analysis, and interpretation of data; writing of the report; nor the decision to submit the report for publication.

Data availability The data that support the findings of this study are not publicly available due to containing information that could compromise the privacy of research participants. Further inquiries can be directed to the corresponding author.

Declarations

Conflict of interest The authors have no conflicts of interest to declare.

Ethical standards Participants have given their written informed consent, and this study was reviewed and approved by the Institutional Review Board committee at the University of California Irvine, approval number HS#2012-9045.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kalantar-Zadeh K, Lockwood MB, Rhee CM, Tantisattamo E, Andreoli S, Baldacci A et al (2022) Patient-centered approaches for the management of unpleasant symptoms in kidney disease. Nature Rev Nephrol 2022:1–4
2. Cabrera VJ, Hansson J, Kliger AS, Finkelstein FO (2017) Symptom management of the patient with CKD: the role of dialysis. Clin J Am Soc Nephrol 12(4):687–693
3. Kalantar-Zadeh K, Wightman A, Liao S (2020) Conservative vs preservative management of chronic kidney disease: similarities and distinctions. Curr Opin Nephrol Hypertens 29(1):92–102
4. Rhee CM, Nguyen DV, Nyamathi A, Kalantar-Zadeh K (2020) Novel conservative management of chronic kidney disease via dialysis-free interventions. Curr Opin Nephrol Hypertens 30(1):97–107
5. Davison SN, Jhangri GS (2010) Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Pain Symptom Manage 39(3):477–485
6. Flynhe JE, Tugman MJ, Narendra JH, Dorough A, Hilbert J, Assimom MM et al (2020) Feasibility of Tablet-Based Patient-Reported Symptom Data Collection Among Hemodialysis Patients. Kidney Int Rep 5(7):1026–1039
7. Weisbord SD, Fried LF, Mor MK, Resnick AL, Unruh ML, Palevsky PM et al (2007) Renal provider recognition of symptoms in patients on maintenance hemodialysis. J Am Soc Nephrol 2(5):960–967
8. Harley KT, Streja E, Rhee CM, Molnar MZ, Kovesdyp C, Amin AN et al (2013) Nephrologist caseload and hemodialysis patient survival in an urban cohort. J Am Soc Nephrol 24(10):1678–1687
9. Abdel-Kader K, Unruh ML, Weisbord SD (2009) Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol 4(6):1057–1064
10. Weisbord SD, Fried LF, Arnold RM, Fine MJ, Levenson DJ, Peterson RA et al (2005) Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 16(8):2487–2494
11. Zamanian H, Taheri KZ (2015) Translation and psychometric properties of the persian version of the dialysis symptom index in hemodialysis patients. Nephro-Urol Mon 7(1):e23152
12. Almutary H, Bomer A, Douglas C (2015) Arabic translation, adaptation and modification of the dialysis symptom index for chronic kidney disease stages four and five. BMC Nephrol 16:36
13. Chaiviboontham S, Phinitkhajorndech N, Tiansaard J (2020) Symptom clusters in patients with end-stage renal disease undergoing hemodialysis. Int J Nephrol Renovasc Dis 13:297–305
14. Cho MK, Kim SY, Shim HY (2018) Validity and reliability of the korean version of the dialysis symptom index for hemodialysis patients. J Nurs Res 26(6):399–410
15. van der Willik EM, Hemmeler MH, Bart HAJ, van Itersum FJ, Hoogendijk-van den Akker JM, Bos WJW et al (2021) Routinely measuring symptom burden and health-related quality of life in dialysis patients: first results from the Dutch registry of patient-reported outcome measures. Clin Kidney J 14(6):1535–1544
16. Weisbord SD, Bossoala M, Fried LF, Giungi S, Tazza L, Palevsky PM et al (2008) Cultural comparison of symptoms in patients on maintenance hemodialysis. Hemodial Int 12(4):434–440
17. Weisbord SD, Fried LF, Unruh ML, Kimmel PL, Jiayi K et al (2019) The impact of race and ethnicity upon health-related quality of life and mortality in dialysis patients. Kidney Med 1(5):253–262
18. Narasaki Y, Okuda Y, Kalantar SS, Yu AS, Novoa A, Nguyen T et al (2021) Dietary potassium intake and mortality in a prospective hemodialysis cohort. J Ren Nutr 31(4):411–420
19. Rhee CM, Nguyen DV, Moradi H, Brunelli SM, Dukkipati R, Jing J et al (2015) Association of adiponectin with body composition and mortality in hemodialysis patients. Am J Kidney Dis 66(2):313–321
20. You AS, Kalantar-Zadeh K, Obi Y, Novoa A, Peralta RA, Streja E et al (2020) Residual urine output and mortality in a prospective hemodialysis cohort. Kidney Int Rep 5(5):643–653
21. Kalandar SS, You AS, Norris KC, Nakata T, Novoa A, Juarez K et al (2019) The impact of race and ethnicity upon health-related quality of life and mortality in dialysis patients. Kidney Med 1(5):253–262
22. Plantinga LC, Drenkard C, Patzer RE, Klein M, Kramer MR, Pastan S et al (2015) Sociodemographic and geographic predictors of quality of care in United States patients with end-stage renal disease due to lupus nephritis. Arthritis Rheumatol 67(3):761–772
23. You AS, Kalantar-Zadeh K (2018) Precision medicine in the transition to dialysis and personalized renal replacement therapy. Semin Nephrol 38(4):325–335

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.